Treatment of anemia in patients with heart disease: A systematic review

Annals of Internal Medicine

Volumn 159, Issue 11, 2013, Pages 746-757

  Kansagara, Devan ^a,b   Dyer, Edward ^a,b   Englander, Honora ^a   Fu, Rongwei ^a   Freeman, Michele ^a,b   Kagen, David ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ADULT DISEASE; ANEMIA; BLEEDING; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CRITICALLY ILL PATIENT; DEEP VEIN THROMBOSIS; DRUG DOSE TITRATION; EXERCISE TOLERANCE; FRACTURE FIXATION; GASTROINTESTINAL DISEASE; HEART CATHETERIZATION; HEART DISEASE; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HEMOGLOBIN BLOOD LEVEL; HIP FRACTURE; HUMAN; HYPERTENSION; IATROGENIC DISEASE; IRON DEFICIENCY ANEMIA; IRON THERAPY; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEW YORK HEART ASSOCIATION CLASS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; STABLE ANGINA PECTORIS; SYSTEMATIC REVIEW; SYSTOLIC HEART FAILURE; TRANSIENT ISCHEMIC ATTACK;

EID: 84890289353     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-159-11-201312030-00007     Document Type: Review

References (81)

1. Boyd CM, Leff B, Wolff JL, Yu Q, Zhou J, Rand C, et al. Informing clinical practice guideline development and implementation: prevalence of coexisting conditions among adults with coronary heart disease. J Am Geriatr Soc. 2011;59:797-805. [PMID: 21568950]
2. Felker GM, Adams KF Jr, Gattis WA, O'Connor CM. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol. 2004;44:959-66. [PMID: 15337204]
3. Malyszko J, Bachorzewska-Gajewska H, Malyszko J, Levin-Iaina N, Iaina A, Dobrzycki S. Prevalence of chronic kidney disease and anemia in patients with coronary artery disease with normal serum creatinine undergoing percutaneous coronary interventions: relation to New York Heart Association class. Isr Med Assoc J. 2010;12:489-93. [PMID: 21337818]
4. O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC, Roger SD, et al; CHARM Committees and Investigators. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 2006;113:986-94. [PMID: 16476847]
5. Kosiborod M, Smith GL, Radford MJ, Foody JM, Krumholz HM. The prognostic importance of anemia in patients with heart failure. Am J Med. 2003;114:112-9. [PMID: 12586230]
6. Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J. 2006;27:1440-6. [PMID: 16717081]
7. da Silveira AD, Ribeiro RA, Rossini AP, Stella SF, Ritta HA, Stein R, et al. Association of anemia with clinical outcomes in stable coronary artery disease. Coron Artery Dis. 2008;19:21-6. [PMID: 18281811]
8. Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005;111:2042-9. [PMID: 15824203]
9. Anand IS. Heart failure and anemia: mechanisms and pathophysiology. Heart Fail Rev. 2008;13:379-86. [PMID: 18236152]
10. González-Costello J, Comín-Colet J. Iron deficiency and anaemia in heart failure: understanding the FAIR-HF trial. Eur J Heart Fail. 2010;12:1159-62. [PMID: 20855375]
11. Kansagara D, Dyer EA, Englander H, Freeman M, Kagen D. Treatment of Anemia in Patients with Heart Disease: A Systematic Review. VA-ESP Project no. 05-225. 2011. Accessed at www.hsrd.research.va.gov/publications/esp/anemia.cfm on 18 October 2013.
12. Higgins JP, Altman DG, Sterne JA, eds. Part 2, Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.10 (updated March 2011). The Cochrane Collaboration; 2008. Accessed at www.cochrane-handbook.org on 12 June 2013.
13. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490. [PMID: 15205295]
14. Norris S, Atkins D, Bruening W, Fox S, Johnson E, Kane R, et al. Selecting observational studies for comparing medical interventions. In: Methods Guide for Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; 2010. Accessed at www.effectivehealthcare.ahrq. gov/ehc/products/196/454/MethodsGuideNorris-06042010.pdf on 18 October 2013.
15. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. Accessed at www.ohri.ca/programs/clinical-epidemiology/oxford.asp on 1 October 2012.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. [PMID: 3802833]
17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34. [PMID: 9310563]
18. Bush RL, Pevec WC, Holcroft JW. A prospective, randomized trial limiting perioperative red blood cell transfusions in vascular patients. Am J Surg. 1997;174:143-8. [PMID: 9293831]
19. Carson JL, Terrin ML, Barton FB, Aaron R, Greenburg AG, Heck DA, et al. A pilot randomized trial comparing symptomatic vs. hemoglobin leveldriven red blood cell transfusions following hip fracture. Transfusion. 1998;38:522-9. [PMID: 9661685]
20. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, et al; FOCUS Investigators. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med. 2011;365:2453-62. [PMID: 22168590]
21. Besarab A, Goodkin DA, Nissenson AR; Normal Hematocrit Cardiac Trial Authors. The normal hematocrit study-follow-up [Letter]. N Engl J Med. 2008;358:433-4. [PMID: 18216370]
22. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-90. [PMID: 9718377]
23. Cooper HA, Rao SV, Greenberg MD, Rumsey MP, McKenzie M, Alcorn KW, et al. Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT Randomized Pilot Study). Am J Cardiol. 2011;108:1108-11. [PMID: 21791325]
24. Hébert PC, Yetisir E, Martin C, Blajchman MA, Wells G, Marshall J, et al; Transfusion Requirements in Critical Care Investigators for the Canadian Critical Care Trials Group. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med. 2001;29:227-34. [PMID: 11246298]
25. Carson JL, Brooks MM, Abbott JD, Chaitman B, Kelsey SF, Triulzi DJ, et al. Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J. 2013;165:964-971.e1. [PMID: 23708168]
26. Hebert PC, Szick S. The anemic patient in the ICU: how much does the heart tolerate? Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie. 2001;36 Suppl 2:S94-100.
27. Chase AJ, Fretz EB, Warburton WP, Klinke WP, Carere RG, Pi D, et al. Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). Heart. 2008;94:1019-25. [PMID: 18332059]
28. Doyle BJ, Ting HH, Bell MR, Lennon RJ, Mathew V, Singh M, et al. Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005. JACC Cardiovasc Interv. 2008;1:202-9. [PMID: 19463301]
29. Jani SM, Smith DE, Share D, Kline-Rogers E, Khanal S, O'Donnell MJ, et al. Blood transfusion and in-hospital outcomes in anemic patients with myocardial infarction undergoing percutaneous coronary intervention. Clin Cardiol. 2007;30:II49-56. [PMID: 18228652]
30. Jolicoeur EM, O'Neill WW, Hellkamp A, Hamm CW, Holmes DR Jr, Al-Khalidi HR, et al APEX-AMI Investigators. Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Eur Heart J. 2009;30:2575-83. [PMID: 19596659]
31. Kim P, Dixon S, Eisenbrey AB, O'Malley B, Boura J, O'Neill W. Impact of acute blood loss anemia and red blood cell transfusion on mortality after percutaneous coronary intervention. Clin Cardiol. 2007;30:II35-43. [PMID: 18228650]
32. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92:930-5. [PMID: 14556868]
33. Maluenda G, Lemesle G, Syed A, Collins SD, Ben-Dor I, Li Y, et al. Should patients who develop anemia (hematocrit (less-than or equal to) 27%) after percutaneous coronary intervention be transfused? J Am Coll Cardiol. 2009;53:A84.
34. Maluenda G, Lemesle G, Ben-Dor I, Collins SD, Syed AI, Li Y, et al. Value of blood transfusion in patients with a blood hematocrit of 24% to 30% after percutaneous coronary intervention. Am J Cardiol. 2009;104:1069-73. [PMID: 19801026]
35. Maluenda G, Lemesle G, Syed A, Collins SD, Ben-Dor I, Li Y, et al. Does transfusion for major bleeding after percutaneous coronary intervention impact clinical outcome in patients admitted with normal hematocrit? J Am Coll Cardiol. 2009;53:A72.
36. Nikolsky E, Mehran R, Sadeghi HM, Grines CL, Cox DA, Garcia E, et al. Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. JACC Cardiovasc Interv. 2009;2:624-32. [PMID: 19628185]
37. Yatskar L, Selzer F, Feit F, Cohen HA, Jacobs AK, Williams DO, et al. Access site hematoma requiring blood transfusion predicts mortality in patients undergoing percutaneous coronary intervention: data from the National Heart, Lung, and Blood Institute Dynamic Registry. Catheter Cardiovasc Interv. 2007;69:961-6. [PMID: 17421023]
38. Aggarwal C, Panza JA, Cooper HA. Does the relation between red blood cell transfusion and mortality vary according to transfusion indication? A case-control study among patients with acute coronary syndromes. Coron Artery Dis. 2011;22:194-8. [PMID: 21169814]
39. Alexander KP, Chen AY, Wang TY, Rao SV, Newby LK, LaPointe NM, et al; CRUSADE Investigators. Transfusion practice and outcomes in non-STsegment elevation acute coronary syndromes. Am Heart J. 2008;155:1047-53. [PMID: 18513518]
40. Aronson D, Dann EJ, Bonstein L, Blich M, Kapeliovich M, Beyar R, et al. Impact of red blood cell transfusion on clinical outcomes in patients with acute myocardial infarction. Am J Cardiol. 2008;102:115-9. [PMID: 18602505]
41. Athar MK, Bagga S, Nair N, Punjabi V, Vito K, Schorr C, et al. Risk of cardiac arrhythmias and conduction abnormalities in patients with acute myocardial infarction receiving packed red blood cell transfusions. J Crit Care. 2011;26:335-41. [PMID: 20869199]
42. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292:1555-62. [PMID: 15467057]
43. Shishehbor MH, Madhwal S, Rajagopal V, Hsu A, Kelly P, Gurm HS, et al. Impact of blood transfusion on short- and long-term mortality in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2009;2:46-53. [PMID: 19463397]
44. Singla I, Zahid M, Good CB, Macioce A, Sonel AF. Impact of blood transfusions in patients presenting with anemia and suspected acute coronary syndrome. Am J Cardiol. 2007;99:1119-21. [PMID: 17437739]
45. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med. 2001; 345:1230-6. [PMID: 11680442]
46. Yang X, Alexander KP, Chen AY, Roe MT, Brindis RG, Rao SV, et al CRUSADE Investigators. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol. 2005;46:1490-5. [PMID: 16226173]
47. Garty M, Cohen E, Zuchenko A, Behar S, Boyko V, Iakobishvili Z, et al; Heart Failure Survey in ISrael (HFSIS) Investigators. Blood transfusion for acute decompensated heart failure-friend or foe? Am Heart J. 2009;158:653-8. [PMID: 19781427]
48. Kao DP, Kreso E, Fonarow GC, Krantz MJ. Characteristics and outcomes among heart failure patients with anemia and renal insufficiency with and without blood transfusions (public discharge data from California 2000-2006). Am J Cardiol. 2011;107:69-73. [PMID: 21146689]
49. Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340:409-17. [PMID: 9971864]
50. Carson JL, Duff A, Berlin JA, Lawrence VA, Poses RM, Huber EC, et al. Perioperative blood transfusion and postoperative mortality. JAMA. 1998;279:199-205. [PMID: 9438739]
51. Bursi F, Barbieri A, Politi L, Di Girolamo A, Malagoli A, Grimaldi T, et al. Perioperative red blood cell transfusion and outcome in stable patients after elective major vascular surgery. Eur J Vasc Endovasc Surg. 2009;37:311-8. [PMID: 19111480]
52. Glance LG, Dick AW, Mukamel DB, Fleming FJ, Zollo RA, Wissler R, et al. Association between intraoperative blood transfusion and mortality and morbidity in patients undergoing noncardiac surgery. Anesthesiology. 2011;114:283-92. [PMID: 21239971]
53. Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50:1657-65. [PMID: 17950147]
54. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51:103-12. [PMID: 18191732]
55. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436-48. [PMID: 19920054]
56. Comín-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, Lüscher TF, et al. The effect of intravenous ferric carboxymaltose on healthrelated quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur Heart J. 2013;34:30-8. [PMID: 22297124]
57. Comín-Colet J, Ruiz S, Cladellas M, Rizzo M, Torres A, Bruguera J. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes. J Card Fail. 2009;15:727-35. [PMID: 19879457]
58. Szczech LA, Barnhart HX, Sapp S, Felker GM, Hernandez A, Reddan D, et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int. 2010;77:239-46. [PMID: 19890274]
59. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al; TREAT Investigators. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2009;54:59-69. [PMID: 19501439]
60. Palazzuoli A, Silverberg DS, Calabrò A, Spinelli T, Quatrini I, Campagna MS, et al. Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia. J Cardiovasc Pharmacol. 2009;53:462-7. [PMID: 19455052]
61. Parissis JT, Kourea K, Andreadou I, Ikonomidis I, Markantonis S, Ioannidis K, et al. Effects of darbepoetin alfa on plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2009;103:1134-8. [PMID: 19361602]
62. Kourea K, Parissis JT, Farmakis D, Paraskevaidis I, Panou F, Filippatos G, et al. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil. 2008;15:365-9. [PMID: 18525396]
63. Parissis JT, Kourea K, Panou F, Farmakis D, Paraskevaidis I, Ikonomidis I, et al. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J. 2008;155:751.e1-7. [PMID: 18371487]
64. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, et al Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008;117:526-35. [PMID: 18195176]
65. Palazzuoli A, Silverberg DS, Iovine F, Calabrò A, Campagna MS, Gallotta M, et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J. 2007;154:645.e9-15. [PMID: 17892986]
66. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J. 2007;28:2208-16. [PMID: 17681958]
67. Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebocontrolled trial. J Am Coll Cardiol. 2007;49:753-62. [PMID: 17306703]
68. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294-9. [PMID: 12538431]
69. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775-80. [PMID: 11401110]
70. Bellinghieri G, Savica V, De Gregorio C, De Gregorio G. Use of erythropoietin in ischemic and arrhythmic cardiopathy of hemodialyzed patients. Contrib Nephrol. 1994;106:135-7. [PMID: 8174359]
71. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, et al; RED-HF Committees. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013;368:1210-9. [PMID: 23473338]
72. Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabrò A, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 2006;152:1096.e9-15. [PMID: 17161060]
73. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-98. [PMID: 17108343]
74. Gerber DR. Transfusion of packed red blood cells in patients with ischemic heart disease. Crit Care Med. 2008;36:1068-74. [PMID: 18379229]
75. Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK, et al; Clinical Transfusion Medicine Committee of the AABB. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2012;157:49-58. [PMID: 22751760]
76. Norris SL, Atkins D, Bruening W, Fox S, Johnson E, Kane R, et al. Observational studies in systemic reviews of comparative effectiveness: AHRQ and the Effective Health Care Program. J Clin Epidemiol. 2011;64:1178-86. [PMID: 21636246]
77. Chatterjee S, Wetterslev J, Sharma A, Lichstein E, Mukherjee D. Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and diversity-adjusted study sequential analysis. JAMA Intern Med. 2013;173:132-9. [PMID: 23266500]
78. Carson JL, Carless PA, Hébert PC. Outcomes using lower vs higher hemoglobin thresholds for red blood cell transfusion. JAMA. 2013;309:83-4. [PMID: 23280228]
79. Gutzwiller FS, Schwenkglenks M, Blank PR, Braunhofer PG, Mori C, Szucs TD, et al. Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK. Eur J Heart Fail. 2012;14:782-90. [PMID: 22689292]
80. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009;69:739-56. [PMID: 19405553]
81. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011;26:1599-607. [PMID: 20929915]